LONDON, March 25, 2019 – Ascension Healthcare plc (“Ascension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for haemophilia and osteoarthritis, is pleased to announce the appointment of Mark Turrell as National Accounts and Sales Director.
Mark Turrell joins Ascension Healthcare bringing over 25 years of experience in commercial leadership roles in health and beauty companies, having previously been the General Manager and Director of Nelsons – the leading Natural Health Products Company. He has vast experience in commercial strategy, having held senior roles at Coty Beauty, Schwarzkopf and Gillette, and has a successful track record of developing brands across international markets.
Biresh Roy, Chief Executive Officer of Ascension, said: “Mark brings with him a wealth of knowledge and experience in sales, marketing and international business development and we are delighted to have him join our team at Ascension. Mark’s impressive track record of sales growth, key account management and delivering profitable results across international markets will be of great benefit to the team as we look to ramp up sales of Flexiseq internationally. We warmly welcome Mark to the team and are excited to work with him as we grow our Flexiseq business domestically and internationally.”
Mark Turrell, National Accounts and Sales Director at Ascension, said: “Osteoarthritis is a very common condition which affects 20% of adults worldwide and, as such, there is a real need for safe pain-relieving options. Ascension have developed a range of topical drug-free treatments which have been shown to reduce pain and stiffness and improve joint movement without any side-effects. I am looking forward to working with the team to ensure our products are available internationally to offer people relief from this debilitating condition and improved mobility for a more active lifestyle.”
Ascension Healthcare plc is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for the treatment of haemophilia and osteoarthritis. The Company has three products in clinical development for the treatment of haemophilia A and also a range of internationally marketed products for osteoarthritis sufferers. For more information please visit: www.ascension.co.uk/
For more information contact
Ascension Healthcare plc
Biresh Roy, Chief Executive Officer
[email protected] / +44 (0)20 7291 5400
Consilium Strategic Communications
(European Media and Investor Enquiries)
Lindsey Neville, Ashley Tapp
Tel: +44 (0)20 3709 5700 / [email protected]